Immuron Ltd

Immuron Limited is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. The company operates in the biotechnology and pharmaceutical industries, which are subject to rapid and significant technological change and are highly competitive, with competitors including major pharmaceutical companies, biotechnology firms, universities, and other research institutions. The company's platform technology is based on oral polyclonal immunoglobulins, which can be used to block viruses or bacteria at mucosal surfaces and neutralize the toxins they produce. The platform enables the development of medicines across a large range of infectious diseases and can be commercialized through most regulatory pathways, including prescription, medical foods, over-the-counter medicines, and dietary supplements.

The company faces competition from entities developing product candidates for its target disease indications, including companies developing novel treatments and technology platforms based on modalities and technology similar to its own. Named competitors in the field of travelers' diarrhea include Eveliqure Biosciences, Intercell, Lumen Bioscience, Sigmoid Pharma, and Scandinavian BioPharma, while competitors in C. difficile therapeutics include Acurx Pharmaceuticals, BiomeBank, Crestone Pharma, Deinove, LPOXY Therapeutics, Lumen Bioscience, and Vedanta Biosciences. The company believes its collaborations with the U.S. Department of Defense are a powerful validation of the potential of its platform, and its intellectual property protection strategy, grounded in securing composition of matter patents, is believed to position it to gain broad and strong protection for its assets.

The company generates revenue from the transfer of hyperimmune products at a point in time, primarily through the sale of its flagship commercial product Travelan® in Australia, the United States, and Canada, and ProIBS® in Australia. The company also has a research and development segment focused on advancing its clinical-stage product candidates. The company's revenue is derived from product sales, and it has never generated any revenue from prescription product sales. The company's customer segments include pharmacies throughout Australia, as well as consumers in the U.S. and Canada, and it is actively pursuing a development and commercialization partner for its lead drug candidate.

The company's flagship commercial product is Travelan®, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers' diarrhea, reduce the risk of minor gastro-intestinal disorders, and is antimicrobial. Travelan® is sold in pharmacies throughout Australia, is licensed as a natural health product in Canada, and is marketed in the U.S. as a dietary supplement for digestive tract protection. In fiscal year 2026, Travelan® sales in Australia were A$5,672,501 ¹, in the United States were A$1,768,411 ², and in Canada were A$165,669 ³. The company also markets ProIBS®, an over-the-counter orally administered product containing the proprietary ingredient AVH200® which has a unique dual mode of action, forming a gentle hydrogel film inside the gut, creating a protective, non-invasive barrier that supports the intestinal lining, balances microflora, and helps soothe irritable bowel syndrome (IBS) symptoms. ProIBS® is indicated for the relief of symptoms of medically diagnosed Irritable Bowel Syndrome, and in fiscal year 2026, ProIBS® sales in Australia were A$85,221 ⁴. Protectyn® (AUST L 231001) was sold online and in health practitioner clinics and marketed as an immune supplement, but the company cancelled and removed the product from the Australian Register for Therapeutic Goods in June 2026; Protectyn® sales in Australia in fiscal year 2026 were A$21,799 ⁵.

The company has two lead drug candidates entering the clinical development phase: IMM-124E for Enterotoxigenic Escherichia coli (ETEC) infections and travelers' diarrhea, and IMM-529 for Clostridioides difficile (C.difficile) infections. The company was awarded a USD $3.43 million ⁶ grant from the US Department of Defense to test the efficacy of one large daily dose regimen of Travelan® in a controlled human infection model (CHIM) clinical study using the ETEC strain H10407. The US Naval Medical Research Command (NMRC) was also awarded over USD $1 million ⁷ in a separate grant to provide immunological support for the Immuron clinical program. The company submitted an Investigational New Drug (IND) application with the FDA and obtained approval in December 2022. On October 4, 2022, Immuron announced execution of a clinical trial master service agreement with Pharmaron CPC, Inc. Up to 60 volunteers were enrolled in the clinical study and were randomly assigned to receive either a once-daily dose of 1200 mg of Travelan® or placebo. On August 8, 2024, additional data analysis of protective efficacy was released reporting a 43.8% ⁸ reduction in diarrhea in the Travelan® group which is approaching statistical significance (p=0.066) ⁹. The company launched ProIBS® in Australia in October 2025.

The company has incurred operating losses in every period since it began operations in 1994, reporting net losses of A$3,679,999 ¹⁰, A$5,215,987 ¹¹, and A$6,936,957 ¹² during the fiscal years ended June 30, 2026, 2025, and 2024, respectively. As of June 30, 2026, the accumulated deficit was A$84,970,154 ¹³. Marketed product sales for fiscal years 2026, 2025, and 2024 were A$7.7 million ¹⁴, A$7.3 million ¹⁵, and A$4.9 million ¹⁶, respectively. As of June 30, 2026, the company had A$9,017,814 ¹⁷ in cash and cash equivalents. The company recognized Research and Development Tax Incentive refunds in the fiscal years ended June 30, 2026 and 2025 of A$782,313 ¹⁸ and A$1,110,577 ¹⁹, respectively, and has recognized a receivable of A$782,313 ²⁰ for the fiscal year ended June 30, 2026.

The company's strategy includes advancing its lead oral polyclonal antibody drug candidates presently in clinical development for the treatment of travelers' diarrhea and to treat recurrent CDI, leveraging its technology platform and collaborations to expand its differentiated polyclonal-based product pipeline across multiple indications including various novel anti-infective programs with the U.S. Department of Defense, continuing to invest in and growing Travelan® sales worldwide, including in the U.S., Australia, Canada, and in new markets, and continuing to broaden the portfolio with additional complementary products like ProIBS®.

A key growth vector is the advancement of IMM-124E for the prevention of travelers' diarrhea. The company has an immediate focus on seeking a development and commercialization partner to progress towards FDA approval of Travelan® to prevent travelers' diarrhea. According to the Centers for Disease Control and Prevention (CDC), an estimated 10 million ²¹ international travelers develop travelers' diarrhea every year. Approval of Travelan® as a preventative treatment is expected to significantly increase commercial opportunities in the U.S., particularly as Travelan® is a non-antibiotic treatment having a considerable record of successful treatment. The company was awarded a USD $3.43 million ²² grant from the US Department of Defense to test the efficacy of one large daily dose regimen of Travelan® in a controlled human infection model (CHIM) clinical study using the ETEC strain H10407, and the US Naval Medical Research Command (NMRC) was also awarded over USD $1 million ²³ in a separate grant to provide immunological support for the clinical program.

Another growth vector is the development of IMM-529 for Clostridioides difficile (C.difficile) infections, an infection of the colon caused by the bacteria C.difficile that produces toxins that cause inflammation and severe diarrhea. The company is relying on a single manufacturer, Syntro Health, to develop Good Manufacturing Practice (GMP) processes for IMM-529. The company also plans to expand its product portfolio with complementary products like ProIBS®, which was launched in Australia in October 2025, and to continue investing in mechanism of action studies that expand understanding of its novel mechanism of action across targeted diseases and conditions, potentially identifying new opportunities for investment.

The company expects to receive refunds from the Australian Federal Government's Research and Development Tax Incentive program, under which the government provides a refundable cash offset pegged at 18.5% ²⁴ above the corporate tax rate, which is currently 25% ²⁵ for Immuron, providing a 43.5% ²⁶ refundable tax offset of eligible research and development expenditures by small to medium size Australian entities during the year ended June 30, 2026, which are defined as Australian entities with less than A$20 million ²⁷ in revenue, having a tax loss. There will also be no cap on the refundable tax offset. However, in May 2026, the Australian Federal Government proposed changes to the Research and Development Tax Incentive program including limiting eligibility to core R&D activities, raising the refundable tax offset turnover threshold from Australia $20m to $50m, and restricting refundability to small to medium enterprises less than 10 years old. The refundable offset rate would also increase to 23 per cent ²⁸ plus corporate tax rate, for companies under $50 million in turnover. As Immuron has operated for more than 10 years, these changes—if enacted—may render the company ineligible for future R&D Tax Incentive refunds.

The company's operational outlook includes reliance on third-party manufacturers for its products and product candidates. IMM-124E is currently manufactured by Bovogen Biologicals based in Australia, and the company has an agreement with Syntro Health to manufacture IMM-529. The company also relies on contract manufacturers such as Mayne Pharma International to produce its marketed product, Travelan®. The company is actively seeking additional and back-up manufacturers but may be unsuccessful in its efforts or may incur material additional costs and substantial delays. The company does not have the capacity to manufacture its product candidates on a commercial scale and has not yet secured manufacturing capabilities for commercial quantities of vaccines and hyper-immune bovine colostrum powder for its product candidates.

The company's capital allocation strategy includes investing in research and development activities for the treatment of infectious diseases, commencing new trials for its product candidates IMM-124E for Traveler's Diarrhea and IMM-529 for C. difficile, and potential other assets/indications. The company has never declared or paid cash dividends on its ordinary shares and does not anticipate paying dividends in the foreseeable future, intending to retain all available funds and any future earnings to support its operations and to finance the growth and development of its business. Over the three fiscal years ended June 30, 2026, the total capital expenditure amounted to A$4,993 ²⁹ for purchases of plant and equipment.

The company faces significant headwinds and constraints, including the risk of continuing operating losses and the need to secure additional financing to meet longer-term business objectives. The company may need to raise additional funds through public or private financings and/or through licensing of its assets or strategic alliances, and any shortfall in funding could result in having to curtail or cease operations. The company also faces the risk that proposed changes to the Australian Federal Government's Research and Development Tax Incentive program, if enacted, may render the company ineligible for future R&D Tax Incentive refunds, which would have a negative effect on future cash flows. Additionally, the company depends on a single manufacturer for each of its lead compound IMM-124E and its second clinical asset IMM-529, and on a sole manufacturer to produce finished drug products, which could incur significant costs and delays if replacements are needed.

The company's ability to generate future revenues from commercializing its intellectual property assets depends heavily on its success in increasing sales of commercial products through investment in sales and marketing initiatives, expansion in sales channels and geographies, product development and broader applications, establishing proof of concept in preclinical studies and clinical trials for its product candidates, successfully completing clinical trials, obtaining regulatory and marketing approvals, maintaining, protecting and expanding its intellectual property portfolio, establishing and maintaining successful licenses, collaborations and alliances with third parties, developing a sustainable, scalable, reproducible and transferable manufacturing process, establishing and maintaining supply and manufacturing relationships with third parties, launching and commercializing any product candidates, obtaining market acceptance, obtaining favorable coverage and reimbursement rates, addressing competing technological and market developments, identifying and validating new product candidates, and negotiating favorable terms in any collaboration, licensing or other arrangements.

The company has incurred operating losses in every period since it began operations in 1994, reporting net losses of A$3,679,999 ³⁰, A$5,215,987 ³¹, and A$6,936,957 ³² during the fiscal years ended June 30, 2026, 2025, and 2024, respectively, and as of June 30, 2026, its accumulated deficit was A$84,970,154 ³³, with cash and cash equivalents of A$9,017,814 ³⁴, indicating a need for additional financing to meet longer-term business objectives. The company depends on a single manufacturer for each of its lead compound IMM-124E and its second clinical asset IMM-529, and on a sole manufacturer to produce finished drug products, which could incur significant costs and delays if replacements are needed. The company's ability to use its cumulative carry forward net operating losses, which have a total potential tax benefit of A$16,360,617 ³⁵ at local tax rates, may be subject to limitations, and its U.S. carry forward net operating losses first start to expire in 2035 ³⁶. The company identified a material weakness in its internal control over financial reporting relating to inventory, which could lead to a decline in the price of its ordinary shares and ADSs and make raising capital more difficult. The company faces the risk that proposed changes to the Australian Federal Government's Research and Development Tax Incentive program, if enacted, may render it ineligible for future refunds, which would negatively affect future cash flows.

Management's message emphasizes the company's goal to become one of the leading biopharmaceutical companies developing and commercializing therapeutics to address increased unmet medical needs in the anti-infective area. The critical components of the strategy include advancing lead oral polyclonal antibody drug candidates presently in clinical development for the treatment of travelers' diarrhea and to treat recurrent CDI, leveraging the technology platform and collaborations to expand the differentiated polyclonal-based product pipeline across multiple indications including various novel anti-infective programs with the U.S. Department of Defense, continuing to invest in and growing Travelan® sales worldwide, including in the U.S., Australia, Canada, and in new markets, continuing to broaden the portfolio with additional complementary products like ProIBS®, continuing to invest in mechanism of action studies, and protecting and leveraging the intellectual property portfolio and patents. Management believes that the intellectual property protection strategy, grounded in securing composition of matter patents on the biologics developed, as well as broader patents to protect the technology platform, has best positioned the company to gain broad and strong protection for its assets.